Oregon Psilocybin Advisory Board

Psilocybin Therapy for Patients with Advanced Illness in Oregon

September 30, 2021
in Federal Law, Kathryn Tucker, Oregon, Psychedelics Industry Group
Kathryn Tucker
Oregon Psilocybin Advisory Board,Oregon Psilocybin Services Act,Psilocybin,Right To Try

One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. However, this drug is not presently legally available, as it is classified as a Schedule I drug, severely restricted and regulated by the federal Controlled Substances Act. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Access Pursuant to the Oregon Psilocybin Services Act

Oregon’s Psilocybin Services Act(“PSA”), adopted via initiative in November 2020, makes therapeutic use of psilocybin legal under Oregon state law. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.

The PSA sets out detailed requirements specifying who will be permitted to provide psilocybin therapy and where such therapy can take place. The provider of the therapy must be a licensed “facilitator” pursuant to the statute. Recommendations for the training required of such facilitators are being developed now by a Psilocybin Advisory Board established by the PSA. The Oregon Health Authority will receive these recommendations and adopt rules regarding requisite training, examination, and licensing of facilitators. Other than taking the training the OHA determines necessary and passing the required exam, facilitators need not have any other education or credential beyond a high school diploma to be certified as a facilitator.

Certainly, it is likely that some who pursue a facilitator license will have advanced education and/or credentials in a health care specialty. It is likely that some who are palliative care nurses, end-of-life care doulas, social workers, mental health counselors, and/or physicians will become licensed facilitators pursuant to the PSA.

Administration of the psilocybin and the experiencing of its effects must occur in a licensed “facilitation center”. A subsequent “integration session” must be offered to the client; however, participation in the integration session is not mandatory and this session need not be held at a facilitation center.

Patients with advanced illness who could benefit from psilocybin therapy, and who are able to visit a facilitation center, will be able to receive such therapy at a licensed center. As noted, the integration session could be conducted elsewhere, possibly at the patient’s home or at a clinician’s office. For patients with advanced illness, it would likely be desirable to seek psilocybin therapy from a facilitator knowledgeable in providing care to medically fragile patients with advanced illness. Such providers must of course be aware that while psilocybin therapy under Oregon’s new PSA law will be legal for state law purposes, psilocybin remains illegal under federal law. It is possible that a form of “cooperative federalism” will arise with regard to psilocybin therapy in Oregon. This is a policy where the federal government, the DEA, will refrain from taking prosecutorial action if state law permits, regulates, and carefully controls the use of a drug. The shelter provided by this approach depends on the policy of the U.S. Department of Justice, which can change as the political winds or officeholder changes—as occurred in the case of cannabis.

Access to Psilocybin Therapy Pursuant to Right to Try Laws

In recent years “Right to Try” laws have been adopted by a supermajority of states, including Oregon, and the Federal Congress. These laws recognize that patients with advanced illness ought to be able to access certain investigational drugs for therapeutic use before completion of later-stage clinical trials and the potentially long process of rescheduling. Psilocybin meets the requisites of RTT laws to be deemed an ‘eligible investigational drug’. Under the letter and spirit of these laws, it is intended to be available for this population of patients while still under investigation. Litigation to compel DEA to respect RTT laws and allow access to psilocybin for therapeutic use is pending before the Ninth Circuit Court of Appeals. If Petitioners prevail in this landmark case, access to psilocybin for patients with advanced illness will become available, protected by both state and federal law. Under this scenario, none of the requirements of the PSA would be applicable. Psilocybin therapy would likely be accessed through the patient’s palliative care physician who would obtain a form of permission from the DEA to obtain this investigational drug from a manufacturer. The therapy could take place wherever most convenient to the patient in light of their advanced illness, for example, if the patient were receiving hospice services at home, the therapy could be provided in the patient’s home, or at the office of the palliative care provider.

Conclusion

There is tremendous interest in the benefits of psilocybin for the relief of a variety of distressing mental health conditions, including anxiety and depression in patients with advanced illness. Oregon has stepped forward in enacting the nation’s first psilocybin therapy law, which will make such therapy legal under a heavily regulatory state law regime beginning in 2023; federal exposure will remain unless a policy of nonenforcement is adopted by the US DOJ. Right to Try laws may compel DEA to allow access sooner and more widely across the nation.

Oregon Psilocybin Services Act: September 2021 Update

September 27, 2021
in Dave Kopilak, Oregon, Psychedelics Industry Group
Dave Kopilak (Primary Drafter of Measure 109)
Oregon Measure 109,Oregon Psilocybin Advisory Board,Psilocybin

On September 25, 2021, Tom Eckert and I spoke about the Oregon Psilocybin Services Act at a seminar sponsored by the Cannabis and Psychedelics Law Section of the Oregon State Bar. Tom and Sheri Eckert were the co-petitioners of Oregon Measure 109, and Tom is the chair of the Oregon Psilocybin Advisory Board and the co-chair of the Training Subcommittee.

A slideshow of my presentation can be found here: Oregon Psilocybin Services Act (OSB Cannabis and Psychedelics Law Section CLE 9.25.2021).

Over the past 6 months, the Board and its various subcommittees have held many meetings and discussed many subjects, and specific recommendations are now beginning to formulate. Stay tuned, as we will be providing frequent updates and commentary to the progress of both the Board and the Oregon Health Authority.

If you have questions concerning the Oregon Psilocybin Services Act or any other laws involving psilocybin, entheogenic plants, or psychedelics in general, please contact attorneys Dave Kopilak, Kathryn Tucker, Sean Clancy, Kaci Hohmann, or Alex Berger from our Psychedelics Practice Group.

Oregon Psilocybin Advisory Board Meeting #1

April 5, 2021
in Dave Kopilak, Oregon, Psychedelics Industry Group
Dave Kopilak (Primary Drafter of Measure 109)
Oregon Measure 109,Oregon Psilocybin Advisory Board,Psilocybin

The first meeting of the Oregon Psilocybin Advisory Board (the “Board”) created by Oregon Measure 109 (“M109”) was held on March 31, 2021. The meeting was held remotely on Zoom. Andre Ourso from the Oregon Health Authority (the “OHA”), a nonvoting ex officio member of the Board, led the meeting. An audio replay of the entire three-hour meeting can be found here.

At the outset of the meeting, in a sentimental and thoughtful gesture, everyone bowed their heads for a moment of silence to honor the late Sheri Eckert, one of the chief petitioners of M109.

From a substantive standpoint, the first meeting largely dealt with various administrative matters, including introductions of the Board members, the rules and procedures of the Board, the charter of the Board and the various deadlines imposed by M109, and the ability of the Board to create subcommittees.

There was frequent mention of developing a system based on science and evidence, with a focus on equity and accessibility.

Here are some of the highlights from the meeting:

• The naturopath physician position (which is required by Section 6(1)(b)(D) of M109) has not yet been filled, but will be.

• The Board will eventually elect a chair and vice chair of the Board, but did not do so at the first meeting.

• The Board, at its discretion, will create a number of subcommittees. Subcommittees must be chaired or co-chaired by Board members, but members of the public can be invited to join the subcommittees. Voting matters cannot be delegated to subcommittees, as every voting matter must be approved by the Board. However, it is likely that a significant amount of the substantive research and work will take place at the subcommittee level.

• The Board approved the creation of three subcommittees, together with the chairs of the subcommittees:

° Equity Subcommittee: Rachel Knox and Angela Carter, co-chairs
° Facilitator Training Subcommittee: Tom Eckert, chair
° Research Subcommittee: Todd Korthius and Ali Hamade, co- chair

• All Board meetings and all subcommittee meetings will be open to the public. Communications between Board members about Board business is prohibited.

• There was no public comment period at the first meeting, but the goal is to have a public comment periods at the conclusion of future meetings.

• Future meeting dates for the Board and the various subcommittees will be announced.

We will blog about M109 frequently during the two-year development period leading up to January 2, 2023. Also, the OHA has an M109 implementation page on its website that can be found here.

If you have questions concerning M109 or any other laws involving psilocybin, entheogenic plants, or psychedelics in general, please contact attorneys Dave Kopilak, Kathryn Tucker, Sean Clancy, Kaci Hohmann, or Alex Berger from our Psychedelics Practice Group.

First Meeting of Oregon Psilocybin Advisory Board is Today

March 31, 2021
in Dave Kopilak, Oregon, Psychedelics Industry Group
Dave Kopilak (Primary Drafter of Measure 109)
Oregon Measure 109,Oregon Psilocybin Advisory Board,Psilocybin

The first meeting of the Oregon Psilocybin Advisory Board created by Oregon Measure 109 will take place today, March 31, 2021, from 1:00 p.m. to 4:00 p.m. The meeting will occur on Zoom and is open to the public. The Zoom link to access the meeting is here.

The OHA did not publicly announce the time, date, and place of the meeting until late yesterday.

Members of our Psychedelics Practice Group will be observing the meeting and we will post a blog about it tomorrow.

Posts Tagged:Oregon Psilocybin Advisory Board

Psilocybin Therapy for Patients with Advanced Illness in Oregon

Oregon Psilocybin Services Act: September 2021 Update

Oregon Psilocybin Advisory Board Meeting #1

First Meeting of Oregon Psilocybin Advisory Board is Today

Recent Posts

Categories

FRANCHISE LAW

MERGERS AND ACQUISITIONS

CANNABIS INDUSTRY

PSYCHEDELICS

TAXATION

REAL ESTATE TRANSACTIONS

LAND USE

LITIGATION AND ALTERNATIVE DISPUTE RESOLUTION

INTELLECTUAL PROPERTY

FINANCIAL INSTITUTIONS

EMPLOYMENT LAW

CORPORATE FINANCE AND SECURITIES

COMPLIANCE AND LICENSING

BUSINESS AND CORPORATE